The PDUFA date of January 21, 2027, is the next major catalyst. Traders should monitor for any FDA advisory committee meeting announcements or review updates in the coming months. A positive decision could be transformative for Dyne, while a complete response letter would be a severe setback.
Drug in focus
DYN drug pipeline →z-rostudirsen
▲ Bullish Named in this 8-K- Impact
- Phase
- Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing
- Time to market
- Potential U.S. launch in Q1 2027 if approved — BLA is under FDA Priority Review with a PDUFA target action date of January 21, 2027 (accelerated approval based on dystrophin as a surrogate endpoint).
- Next catalyst
- PDUFA date · Jan 21, 2027 65d
What to watchThe January 21, 2027 PDUFA is the binary to trade: approval odds look favorable (Priority Review, positive Phase 1/2 data, dystrophin surrogate endpoint), but an Accelerated Approval tied to a surrogate plus an unfinished confirmatory trial (FORZETTO) leaves room for a surprise CRL. Watch for an FDA Advisory Committee date in Q4 2026, the Q3 2026 earnings call for any label/launch commentary, and note the heavy 10b5-1 insider selling and ~57% weighted short-volume ratio as overhangs into the decision.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 20 $23.45entry
- T+1 · 4mo ago +1.62%α +0.79% · $23.83
- T+5 · 4mo ago +4.22%α +4.65% · $24.44
- T+20 · 3mo ago +11.51%α +7.39% · $26.15
- T+60 · 5w ago −34.75%α −39.60% · $15.30
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dyne Therapeutics announced FDA acceptance of its BLA for z-rostudirsen (DYNE-251) for Duchenne muscular dystrophy amenable to exon 51 skipping, granted Priority Review with a PDUFA target date of January 21, 2027. The company expects a potential U.S. launch in Q1 2027 if approved, marking a significant regulatory milestone for this clinical-stage biotech.
Key Facts
- FDA accepted BLA for z-rostudirsen (DYNE-251) for DMD exon 51 skipping
- Priority Review granted with PDUFA target action date of January 21, 2027
- Company expects potential U.S. launch in first quarter of 2027, assuming approval
Financial Impact
No financial figures provided in the filing; approval could unlock significant revenue potential in DMD market
Risk Factors
- FDA may not approve the BLA or may require additional clinical data
- Potential delays in review timeline or advisory committee outcomes
- Competition from existing DMD therapies (e.g., Exondys 51, Vyondys 53) and other exon-skipping candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-308343 |
| Document: 0001193125-26-308343-index-headers.html | 0001193125-26-308343 |
| Document: 0001193125-26-308343-index.html | 0001193125-26-308343 |
| Document: 0001193125-26-308343.txt | 0001193125-26-308343 |
Track record
54 reports on DYN
11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers